What is Newomics?
Newomics specializes in the engineering of high-performance devices for liquid chromatography-mass spectrometry (LC-MS), most notably through its proprietary UniESI system and MEA chip technology. These innovations are engineered to address the complex requirements of metabolomics, proteomics, and clinical mass spectrometry. By offering plug-and-play compatibility, the company effectively lowers the barrier to entry for high-throughput analysis, serving a diverse clientele that spans biomarker discovery, environmental monitoring, and pharmaceutical research. Their market position is defined by a focus on robust, scalable performance that bridges the gap between laboratory research and clinical application.
How much funding has Newomics raised?
Newomics has raised a total of $11.9M across 3 funding rounds:
Series A
$3.9M
Debt
$150K
Series B
$7.9M
Series A (2018): $3.9M with participation from Undisclosed
Debt (2020): $150K led by PPP
Series B (2020): $7.9M supported by LDV Partners, MSA Capital, Photon Fund, and Berkeley Catalyst Fund
Key Investors in Newomics
LDV Partners
LDV Partners is a venture firm focused on transforming innovative ideas into successful companies by providing strategic insights and hands-on support to founders in disruptive technology sectors.
MSA Capital
MSA Capital is an independent global private equity and venture capital firm that partners with entrepreneurs to build innovative companies capable of delivering strong financial and social returns.
Berkeley Catalyst Fund
Berkeley Catalyst Fund is a Cupertino-based venture capital firm dedicated to providing essential benefits and capital to early-stage entrepreneurial startups.
What's next for Newomics?
With the recent infusion of capital, Newomics is poised to transition into a more aggressive phase of commercial expansion and technological refinement. The strategic focus will likely center on deepening the integration of their MEA chip technology within existing clinical workflows, thereby enhancing the diagnostic utility of their platforms. Furthermore, the company is expected to leverage these resources to bolster its R&D capabilities, ensuring that its multiomics solutions remain at the forefront of the industry. As the firm matures, the emphasis will shift toward establishing broader partnerships within the global life sciences sector, ultimately aiming to standardize high-sensitivity LC-MS analysis across both academic and commercial research institutions.
See full Newomics company page
